Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People whose general health and ability to carry out daily activities meets a certain minimum level, as assessed by their doctor (confirm with trial site)
• People with a life expectancy of at least 3 months
• People who are willing and able to follow the study requirements, in their doctor's opinion
• People who have given written consent to participate, understanding they may withdraw at any time without it affecting their future care
• People diagnosed with chronic lymphocytic leukaemia (CLL), B-cell lymphomas, or multiple myeloma (MM), who are not eligible to receive the currently available treatments for their condition
• People whose blood counts and organ function results meet specific minimum levels — including red blood cells, platelets, white blood cells, liver function, and kidney function — without having needed certain medical support in the 7 days before testing (confirm with trial site for exact values)
• People whose heart pumping function, as measured by an ultrasound of the heart, meets a minimum threshold set by the trial or the treating hospital

Who may not be able to join:

• People who still have significant ongoing side effects from previous treatments (note: hair loss and mild nerve-related symptoms may be acceptable — confirm with trial site)
• Women who are pregnant or breastfeeding
• People of reproductive potential who are not using an effective form of contraception as specified by the trial (confirm with trial site for the full list of accepted methods)
• People with a history of another cancer in the past five years, except for certain minor skin cancers or non-invasive cancers (confirm with trial site)
• People with a history of clinically significant low blood pressure
• People with a history of clinically significant allergic or hypersensitivity reactions
• People with a known history of significant blood vessel disease or a high risk of blood vessel problems — including blood clots, peripheral arterial disease, or inflammation of the blood vessels — as assessed by their treating doctor
• People with a history of heart failure, chest pain (angina), or a heart attack within the past 12 months
• People with high blood pressure or heart rhythm problems that are not well controlled (for example, requiring a medication change in the past 3 months or a hospital admission in the past 6 months)
• People with a history of significant neurological or psychiatric disorders
• People with a clinically significant or active infection
• People with significant non-cancerous liver disease, such as cirrhosis or chronic active hepatitis
• People who are HIV-positive, unless they are on antiviral therapy with very low virus levels; people with active Hepatitis B or C infection, unless successfully treated with undetectable virus levels; or people with an active CMV infection
• People who have received other cancer treatments within 14 days before the start of the trial
• People who have had an organ or stem cell transplant from a donor within the past 3 months, or who currently have graft-versus-host disease (a complication of transplants) requiring immune-suppressing medication
• People who are unable to follow the treatment or follow-up schedule required by the trial
• People who have received a COVID-19 vaccine within 72 hours before starting the study treatment (vaccination should occur either more than 72 hours before starting, or after a specific early study period has ended — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.